ABO and Alzheimer disease: However, compared with the AβO + HKL group, CsA treatment (the AβO + HKL + CsA group) markedly increased intracellular Aβ1–42 concentration in the hippocampal neuronal model of AD (p < 0.05) (Figure 6A: F = 69.98, df = 3).